Ignite Creation Date:
2025-12-24 @ 7:30 PM
Ignite Modification Date:
2026-02-27 @ 4:31 PM
Study NCT ID:
NCT03776903
Status:
COMPLETED
Last Update Posted:
2018-12-17
First Post:
2018-12-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000071243', 'term': 'Zika Virus Infection'}], 'ancestors': [{'id': 'D000096724', 'term': 'Mosquito-Borne Diseases'}, {'id': 'D000079426', 'term': 'Vector Borne Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D001102', 'term': 'Arbovirus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018177', 'term': 'Flavivirus Infections'}, {'id': 'D018178', 'term': 'Flaviviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 600}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-04-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-12', 'completionDateStruct': {'date': '2018-09-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-12-13', 'studyFirstSubmitDate': '2018-12-12', 'studyFirstSubmitQcDate': '2018-12-13', 'lastUpdatePostDateStruct': {'date': '2018-12-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-12-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-08-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Positive Percent Agreement and Negative Percent Agreement', 'timeFrame': 'From symptom onset to 12 weeks after symptom onset.', 'description': 'The positive percent agreement (PPA) and negative percent agreement (NPA) of the ZIKV Detect™ 2.0 IgM Capture ELISA versus the reference test.'}], 'secondaryOutcomes': [{'measure': 'Duration of Positive Percent Agreement', 'timeFrame': 'From symptom onset to 12 weeks after symptom onset.', 'description': 'The time period relative to onset of symptoms that a positive result can be identified and the time period after onset of symptoms that the positive percent agreement is maximized and the longest elapsed time after symptom onset that positive test results are observed.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Zika Virus Infection']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.', 'detailedDescription': 'The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples. The FDA guidance document (ZIKA SEROLOGY DE NOVO/510(K) PRE-MARKET SUBMISSIONS - Recommended Analytical and Clinical Studies for Zika Virus IgM Assays; Dated 02Jun2017; FDA/CDRH/OIR/DMD) allows for the utilization of archival serum specimens to evaluate test performance. This study will follow this guidance. Test samples will be collected from endemic sites (both presumed positive and presumed negative samples) and from non-endemic sites (presumed negative samples). All samples will be shipped to the sponsor for randomization and will be tested at three sites in the United States.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Human males and females of varying ages and geographical locations where Zika virus is endemic and not endemic.', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion criteria:\n\n* Human males and females of varying ages and geographical locations where Zika virus is endemic and not endemic.\n* Retrospective (archived) and prospective human serum samples. Archived samples will fall under the category of "leftover" specimens as described by FDA guidance.\n\nExclusion criteria:\n\n• Samples that are not de-identified.'}, 'identificationModule': {'nctId': 'NCT03776903', 'briefTitle': 'Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA', 'organization': {'class': 'INDUSTRY', 'fullName': 'InBios International, Inc.'}, 'officialTitle': 'Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA', 'orgStudyIdInfo': {'id': 'ZIKV-2016-01'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'endemic', 'description': 'Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.', 'interventionNames': ['Other: ZIKV Detect™ 2.0 IgM Capture ELISA']}, {'label': 'non-endemic', 'description': 'Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.', 'interventionNames': ['Other: ZIKV Detect™ 2.0 IgM Capture ELISA']}], 'interventions': [{'name': 'ZIKV Detect™ 2.0 IgM Capture ELISA', 'type': 'OTHER', 'description': 'De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)', 'armGroupLabels': ['endemic', 'non-endemic']}]}, 'contactsLocationsModule': {'locations': [{'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'InBios International', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}], 'overallOfficials': [{'name': 'Frances Chu, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'InBios International'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'InBios International, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Fast-Track Drugs & Biologics, LLC', 'class': 'UNKNOWN'}, {'name': 'Biomedical Advanced Research and Development Authority', 'class': 'FED'}], 'responsibleParty': {'type': 'SPONSOR'}}}}